Molecular Formula | C38H47Br2N9O5 |
Molar Mass | 869.65 |
Density | 1.497 |
Boling Point | 1091.9±65.0 °C(Predicted) |
pKa | 6.80±0.25(Predicted) |
Storage Condition | -20℃ |
Use | Olcegepant(BIBN 4096; BIBN 4096BS) is a non-peptide CGRP1 receptor selective antagonist, IC50 is 0.03 nM. |
In vitro study | Olcegepant possesses higher affinity for the human CGRP receptor than the endogenous ligand CGRP and 150-fold higher affinity compared to the peptidic antagonist CGRP8-37. Olcegepant reverses CGRP-mediated vasodilation in human cerebral vessels and inhibits neurogenic vasodilation in a surrogate animal model of migraine pathophysiology. Olcegepant (BIBN4096BS) is extremely potent at primate CGRP receptors exhibiting an affinity (K i ) for human CGRP receptors of 14.4±6.3 (n=4) pM. Several lines of evidence suggest that a calcitonin-gene related peptide (CGRP) receptor antagonist may serve as a novel abortive migraine treatment. Olcegepant (BIBN4096BS) exhibits competitive antagonism at the CGRP receptor present in SK-N-MC cells. Isolated human cerebral, coronary, and omental arteries are studied with a sensitive myograph technique. CGRP induces a concentration-dependent relaxation that is antagonized by Olcegepant in a competitive manner. |
In vivo study | Olcegepant (BIBN4096BS) in doses between 1 and 30 μg/kg (i.v.) inhibits the effects of CGRP, released by stimulation of the trigeminal ganglion, on facial blood flow in marmoset monkeys. Pre-treatment with Olcegepant (900 μg/kg) inhibits the capsaicin-induced expression of Fos throughout the spinal trigeminal nucleus by 57%. In contrast, the expression of phosphorylated extracellular signal-regulated kinase in the trigeminal ganglion is not changed by Olcegepant pre-treatment. Olcegepant (0.3 to 0.9 mg/kg, i.v.) markedly reduces mechanical allodynia in CCI-ION rats. Olcegepant (0.6 mg/kg, i.v.) significantly reduces the number of c-Fos immunolabeled cells in spinal nucleus of the trigeminal nerve and upregulation of ATF3 transcript (a marker of neuron injury) but not that of interleukin-6 in trigeminal ganglion of CCI-ION rats. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.15 ml | 5.749 ml | 11.499 ml |
5 mM | 0.23 ml | 1.15 ml | 2.3 ml |
10 mM | 0.115 ml | 0.575 ml | 1.15 ml |
5 mM | 0.023 ml | 0.115 ml | 0.23 ml |